Analysts fell to the sidelines weighing in on Acer Therapeutics Inc (ACER) and Amgen Inc (AMGN) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Acer Therapeutics Inc (ACER)
In a report released yesterday, Tim Lugo from William Blair maintained a Hold rating on Acer Therapeutics Inc. The company’s shares opened today at $2.72, close to its 52-week low of $2.57.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 5.3% and a 37.1% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Aclaris Therapeutics Inc.
Acer Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.
See today’s analyst top recommended stocks >>
Amgen Inc (AMGN)
In a report issued on July 30, Matt Phipps from William Blair reiterated a Hold rating on Amgen Inc. The company’s shares opened today at $186.
According to TipRanks.com, Phipps is ranked 0 out of 5 stars with an average return of -26.0% and a 14.8% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Kezar Life Sciences Inc, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Currently, the analyst consensus on Amgen Inc is a Strong Buy with an average price target of $213.80, representing a 14.9% upside. In a report issued on July 30, J.P. Morgan also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
